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ABSTRACT
Trastuzumab (Herceptin) is used in neoadjuvant, adjuvant 
and metastatic breast cancer. Infusion reactions are a 
common side effect most of which are mild and easily 
managed, anaphylaxis occurs rarely. The summary 
of product characteristics recommends observation 
for 6 hours after the commencement of the first 
administration; we wanted to evaluate this practice. We 
assessed first administrations of trastuzumab infusions 
retrospectively to determine both rate and timing of 
reactions. Medical and nursing notes of 94 patients 
who had been prescribed intravenous trastuzumab in 
2012 were reviewed; 2 additional patients did not have 
records available. Fourteen patients received palliative, 
73 adjuvant and 7 neoadjuvant trastuzumab.r. Two 
(2%) had a reaction to trastuzumab occurring at 70 
and 80 min from infusion commencement. We did not 
observe a reaction in the 4.5 hours after the 90 min 
infusion was complete. We recommend discharge 
with verbal and written advice immediately after 
uncomplicated first administration.
INTRODUCTION
Trastuzumab (Herceptin) is a recombinant human-
ised IgG1 monoclonal antibody that targets the 
human epidermal growth factor 2 (HER2) protein, 
a member of the epidermal growth factor receptor 
tyrosine kinase receptor family. Approximately 20% 
of human breast cancers overexpress HER2.1 This 
is assessed clinically by flourescent in situ hybridisa-
tion or immunohistochemistry gene amplification.
For breast cancer overexpressing HER2, the addi-
tion of neoadjuvant trastuzumab has been shown 
to increase pathological complete response (pCR) 
rate.2 Adjuvant trastuzumab improves progression 
free survival (PFS), response rate (RR)3 and overall 
survival (OS).4 In metastatic disease, trastuzumab 
with paclitaxel or monotherapy after first-line 
chemotherapy improves OS, PFS and RR.5 Dual 
anti-HER2 therapy, a combination of pertuzumab 
and trastuzumab plus docetaxel is now treatment 
of choice as first line in the metastatic setting.1 Dual 
anti-HER2 therapy plus docetaxel increases pCR 
rate and has become standard in the neoadjuvant 
setting in the UK as approved by National Institute 
for Health and Care Excellence.6 Trastuzumab is 
administered as an infusion or more recently as a 
subcutaneous injection every 3 weeks.7
Trastuzumab side effects include pulmonary and 
cardiac toxicity, including left ventricular dysfunc-
tion.1 Infusion-related reactions (IRR) are managed 
with oral medication and reported in up to 40%, 
with anaphylaxis in 0.25% of patients.8 Onset of 
mild-to-moderate symptoms such as chills, fever, 
hypotension and dyspnoea are classified as an IRR; 
these symptoms are poorly defined and so lead to a 
variation in IRR rates in the literature. A retrospec-
tive review of 197 patients demonstrated IRR in 
16% and anaphylaxis in 1%.9 A large retrospective 
analysis of 25 000 patients shows anaphylaxis in 
0.3% of patients.10 It is clear from the literature that 
IRR and anaphylaxis occur most frequently during 
or immediately after the first infusion.8–10
There are rare postmarketing reports of severe 
and fatal episodes of anaphylaxis and pulmonary 
toxicity. A meta-analysis included 22 randomised 
control trials and found that fatal adverse events for 
those receiving HER2 blockade (trastuzumab) were 
not statistically different to those in the non-HER2 
blockade group.11 A PubMed search generates 
one case12 of severe pulmonary toxicity occurring 
90 min into the first infusion, a second developing 
severe infusion reaction after 2 min of the first infu-
sion13 and a third developing severe infusion reac-
tion after 30 min of the first infusion.14
Severe infusion reactions/anaphylaxis and IRR 
are seldom identified during the period of observa-
tion after completing trastuzumab infusion. Thus, 
we hypothesise that the period of observation after 
the first infusion is clinically unnecessary and costly 
to the National Health Service. We performed this 
review to determine if a period of observation was 
necessary.
MATERIALS AND METHODS
Our sample consisted of 96 female patients 
with breast cancer who had been prescribed at least 
one cycle of Intravenous trastuzumab between I 
January 2012 and 31 December 2012, generated 
from in-house pharmacy software. Medical and 
nursing notes were retrospectively reviewed for 
documentation of trastuzumab reactions during the 
6-hour stay from the start of the first infusion. Data 
were stored and processed on confidential Excel 
files. A retrospective approach was taken to reduce 
IRR reporting bias and to aid rapid data collec-
tion. From the list of 96 patients, 2 patients were 
excluded; in both instances, detailed records were 
not available.
RESULTS
The total sample size consisted of 94 female patients 
with a mean age of 54 years. Fourteen patients 
received palliative, 73 adjuvant and 7 neoadjuvant 
trastuzumab. Seventeen had a documented allergy 
to at least one drug. Two patients had a reaction to 
docetaxel prior to trastuzumab; neither went on to 
react to trastuzumab.
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Ninety two of 94 (97.9%) had no reaction to first dose of tras-
tuzumab during the infusion or subsequent period of observa-
tion. Two had a reaction during the first infusion of trastuzumab 
(2.1%) and we document these here:
Case 1
Forty four-year-old patient with right-sided grade 3, T2N0M0 
ER-positive and HER2-positive ductal carcinoma of the breast 
treated with adjuvant E-CMF (epirubicin, cyclophosphamide, 
methotrexate and 5-fluorouracil) chemotherapy. She had no 
history of allergies, took citalopram for depression and had 
no other significant past medical history. Seventy minutes after 
commencing the first infusion, she described feeling cold and 
was observed to be shivering. The infusion was stopped imme-
diately and she received 10 mg IV chlorphenamine and 100 mg 
IV hydrocortisone with good effect. The infusion was restarted 
35 min later. She was observed for 4 hours postinfusion with no 
further symptoms or signs of reaction (see figure 1). She did not 
react to the subsequent 17 infusions of trastuzumab and received 
secondary prophylactic chlorphenamine and hydrocortisone.
Case 2
Seventy two-year-old lady with right-sided grade II, T1N1M0 
ER-negative and HER2-positive invasive ductal carcinoma of 
the breast. Comorbidities included previous transient ischaemic 
attack and cardiac arrhythmia controlled with a pacemaker. 
She had not suffered a myocardial infarction and her cardiac 
symptoms were stable. She had documented sensitivities to indo-
methocin and mepore dressings. A pretreatment echocardiogram 
showed an ejection fraction of 64%, and thus she treated with 
adjuvant CMF chemotherapy.
She developed rigours after 80 min of commencing first tras-
tuzumab infusion. The infusion was stopped and she was given 
100 mg IV hydrocortisone and 10 mg IV chlorphenamine. 
After 55 min, the symptoms had resolved and the infusion was 
restarted (see figure 2). She had no further signs or symptoms 
after being observed for 4 hours after the infusion and went 
on to have subsequent infusions without reaction but with the 
co-administration of chlorphenamine and hydrocortisone.
DISCUSSION
IRR are most likely during the first trastuzumab administra-
tion. The cause is unknown but the mechanism is unlikely to 
be IgE-mediated hypersensitivity as there is no prior exposure 
to the molecule. Trastuzumab interacts with HER2 receptors on 
cell membranes which leads to the release of proinflammatory 
cytokines. This may result in symptoms of chills, breathlessness 
and hypotension.2 Thus, IRR are most common at first exposure 
as shown clinically in a retrospective series of 197 patients (1788 
doses) of which IRR occur on only three subsequent infusions.9
The risk of a subsequent reaction to an allergen within 72 hours 
without re-exposure to the trigger is defined as a biphasic reac-
tion. It is the risk of biphasic reaction and delayed acute allergic 
reaction that explains the recommended 4 hours observation 
postinfusion with trastuzumab. The exact mechanism of biphasic 
reactions is unknown; a review of 541 case of anaphylaxis within 
the emergency department found that biphasic reactions were 
more likely with either an unknown precipitant (non-drug-re-
lated reactions) or moderate-to-severe reactions.15
We have documented reactions in only 2 of 94 (2%) patients 
receiving the first trastuzumab infusion, both occurring during 
administration. We provide evidence reactions are unlikely in 
the observation period postadministration of trastuzumab. A 
review of infusion reactions with various monoclonal antibodies 
concluded that reactions are likely to occur within minutes of the 
first infusion.16 Furthermore, a study in 2014 reports infusion 
Figure 1 Case 1 observation chart showing reaction to trastuzumab 
after 70 min.
Figure 2 Case 2 observation chart showing reaction to trastuzumab 
after 80 min.
2 Price L, Brunt AM. Eur J Hosp Pharm 2017;0:1–3. doi:10.1136/ejhpharm-2016-001155
group.bmj.com on March 28, 2017 - Published by http://ejhp.bmj.com/Downloaded from 
Short report
reaction in 1.8% of doses of trastuzumab administered in 197 
cases,9 with the majority of reactions occurring with the first 
dose and all reactions occurred during the infusion (between 
5 and 92 min from start of infusion). As a result of a literature 
review and our own observations, we suggest that the practice 
of observation for a total of 6 hours from the start of the first 
infusion or subcutaneous injection of trastuzumab is unneces-
sary, providing the administration has been uneventful.
Seventeen of 94 patients had documented allergies and 2 of 
94 had previous reactions to chemotherapy but none of these 
reacted to the first infusion of trastuzumab. We have seen a 2% 
rate of IRR, similar to recent reviews and adverse drug reactions 
(ARD) reporting data. We have no evidence of reaction after 
stopping the infusion from our 94 patients which supports the 
published literature.12 14
Adjuvant trastuzumab remains standard for this group of patients 
but a trastuzumab–pertuzumab combination is now licenced for 
first-line metastatic and neoadjuvant therapy. Large studies that 
led to licencing of trastuzumab and pertuzumab in both meta-
static and neoadjuvant setting both report grade III/IV hypersen-
sitivity/anaphylaxis reactions in 2% compared with 2.5% in those 
receiving trastuzumab alone.1 6 Our recommendation to abandon 
the period of observation postinfusion for uncomplicated cases can 
be extrapolated to include those treated with combination therapy.
CONCLUSION
IRR are common and poorly defined, serious anaphylactic reac-
tions are rare and occur during administration of trastuzumab. 
We demonstrate IRR occur in 2% of patients, only during admin-
istration. We recommend discharging patients after uncompli-
cated first and subsequent infusions or subcutaneous injections 
of trastuzumab with verbal and written advice without an addi-
tional period of observation.
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